Drug Profile
Research programme: therapeutics - Re-Pharm
Alternative Names: RP 0217Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Re-Pharm
- Class Anti-inflammatories; Fluoroquinolones; Naphthyridines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Eye disorders; Inflammatory bowel diseases; Neuropathic pain; Respiration disorders; Sexual function disorders
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Eye disorders in United Kingdom (Topical)
- 13 Sep 2023 Discontinued - Preclinical for Inflammatory bowel diseases in United Kingdom (Topical)
- 13 Sep 2023 Discontinued - Preclinical for Respiration disorders in United Kingdom (Topical)